OncoMatch/Clinical Trials/NCT06353126
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
Is NCT06353126 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies non-drug interventions for liver cancer.
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for living donor liver transplantation receive DEB-TACE 2 weeks prior to the surgery. The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS)；2) Pathological response rate (Pathological Response); 3) Proportion of patients completing living donor liver transplantation; 4) Adverse events related to DEB-TACE.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
White blood cell count <3.0x10^9/L, platelet count <50x10^6/L, and unable to correct [excluded]
Kidney function
creatinine >176.8 umol/L or creatinine clearance rate <30ml/min [excluded]
Liver function
Child-Pugh score A-B grade; no severe hepatic encephalopathy; no irreversible hepatic artery to hepatic vein shunt
Cardiac function
Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV) [excluded]; cardiopulmonary insufficiency [excluded]
Child-Pugh score A-B grade; Severe hepatic encephalopathy [excluded]; Renal dysfunction, creatinine >176.8 umol/L or creatinine clearance rate <30ml/min [excluded]; White blood cell count <3.0x10^9/L, platelet count <50x10^6/L, and unable to correct [excluded]; Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV) [excluded]; cardiopulmonary insufficiency [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06353126 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages